The down‐regulation of C1QBP suppresses breast cancer progression but enhances the glycolytic activity of cancer cells,7 suggesting that p32 may serve as a promising diagnostic molecule and therapeutic target for maintaining metabolic balance in cancer biology.13 Here, C1QBP is linked to cancer.